The combination of sotigalimab (APX005M) and nivolumab (Opdivo) elicited durable responses with a reasonable safety profile in patients with melanoma who were refractory to anti–PD-1 therapy, according to data from a phase 2 trial (NCT03123783).
The combination of sotigalimab (APX005M) and nivolumab (Opdivo) elicited durable responses with a reasonable safety profile in patients with melanoma who were refractory to anti–PD-1 therapy, according to data from a phase 2 trial (NCT03123783).
Posted in Melanoma News, Health Professionals, Clinical Trials
Immunotherapy, intralesional treatments, multidisciplinary care teams define rapidly-evolving multimodal approach.
Posted in Melanoma News, Health Professionals, Of Interest
The drug yielded partial responses in 2 of 15 patients in this single-arm, phase 2 study.
Posted in Melanoma News, Health Professionals, Of Interest
Patients with multiple myeloma (MM) may be more likely to develop melanoma than the general population, according to a poster presented at 2022 American College of Mohs Surgery Annual Meeting. They also may face a higher overall but not melanomas-specific mortality rate, the findings showed.
Posted in Melanoma News, Health Professionals, Of Interest